NIH Issues $2.87 Million Drug Development Grant to Cerageneix
News Sep 11, 2009
Ceragenix Pharmaceuticals, Inc. has announced that the National Institutes of Health (NIH) has awarded a $2.87 million grant to fund the pre clinical development of a Ceragenin™ based oral drug to treat two common and potentially deadly gastrointestinal infections: Clostrdium difficile and Shigella. The grant will fund the preclinical development, formulation, toxicology and cGMP scale up to 1 kilogram of CSA-13.
The research grant has been awarded to a consortium of research institutions led by Brigham Young University (BYU) and including SRI International (Menlo Park, CA), Southwest Research Institute (SwRI, San Antonio, TX) and McMaster University (Hamilton, Ontario, Canada). Ceragenins™ are a class of novel antimicrobial compounds that mimic functions of the body’s own innate immune system.
The Ceragenin™ technology was invented by Dr. Paul B. Savage (Reed Izatt Professor at BYU) and has been exclusively licensed by BYU to Ceragenix. There have been over 30 peer reviewed scientific publications on this novel class of compounds.
A new experimental system has been designed that can rapidly assess the pathogenic effects of a drug on a baby's developing brain. The system uses embryonic stem cells reprogrammed into neurons, and offers a powerful tool for probing genetic and molecular underpinnings of drug-induced neurodevelopmental disorders.READ MORE
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE